Global Cancer Registry Software Market is Likely to Generate USD 56.4 Million in 2019

Global Cancer Registry Software Market is Likely to Generate USD 56.4 Million in 2019 Growing Incidence of Cancer in the Americas Makes it a Lucrative Segment for the Global Cancer Registry Software Market Market Overview The worldwide cancer registry software market is likely to hold a market value of USD 56.4 million in 2019. The market has been anticipated to develop at a CAGR of 10.7% over the forecast period.

Cancer registry gathers information about the prevalence (incidence) of cancer, the variations of cancers that occur and their positions within the body, the range of cancer at the time of diagnosis (disease stage), and the available treatments that the patients can receive.

Data gathered by state cancer registries allow public health practitioners to better address and understand the cancer problem. Registry data are vital for targeting programs related to risk-related behaviors (for instance, sun exposure and tobacco use) or on ecological risk factors (for instance, chemical and radiation exposures). Such information is also indispensable for identifying where and when cancer screening efforts should be improved and for tracking the cure offered to cancer patients. Additionally, reliable registry data are essential to a gamut of research endeavors, including those aimed at estimating the efficiency of cancer control, prevention, or treatment programs.

Cancer registry software is a software used for disease registry that is mostly used to maintain and establish a cancer incidence reporting system. It acts as a technology oriented informational resource for the study of cancer and its causes. This type of registry software is substantial as cancer is among the leading causes of global death and therefore the data collection on cancer cases from diagnosis through survival is useful to help recognize trends and eventually progress care for patients that are battling cancer. However, data security-related concerns, privacy and averseness to adopt progressive solutions may hinder the growth of the market over the forecast period.

Market Segmentation The global cancer registry software market has been segmented into deployment model, type, functionality, database type, and end user.

Based on deployment model, the market has been segmented into on-premise models and cloudbased models.

Based on type, the market has been segmented into standalone software and integrated software.

Based on functionality, the market has been segmented into product outcome evaluation, patient care management, medical research, cancer reporting to meet state and federal regulations, and clinical studies.

Based on database type, the market has been segmented into public databases and commercial databases.

Based on end user, the market has been segmented into government organizations, medical device companies, hospitals & medical practices, biotechnology, pharmaceutical, research centers, and others.

Regional Analysis The Americas is expected to lead the global cancer registry software market owing to the growing incidence of cancer, increasing investment in research and development for innovation in the region, and innovative product development. Europe is likely to hold the second largest position in the worldwide cancer registry software market owing to the availability of investment for research and prevalence of strong academic & research base in the European economies. AsiaPacific is likely to be the fastest growing market in the worldwide cancer registry software industry due to the shift of pharmaceutical companies to nations such as China and India, which are lowcost manufacturing regions. The Middle East & Africa has the least share of the worldwide cancer registry software market. Furthermore, the major share of the global cancer registry software market is likely to be held by the Middle East region pertaining to the surging government initiatives for the healthcare sector.

Key Players The global cancer registry software market has been dominated by key players such as Rocky Mountain Cancer Data Systems, Onco, Inc., Elekta AB (PUB), McKesson Corporation, Electronic Registry Systems, Inc., C/Net Solutions, Ordinal Data Inc, McKesson Corporation, IBM, Conduent Inc, and Himagine Solutions Inc.